Testing for PIK3CA/AKT1/PTEN alterations was carried out using FoundationOne®CDx, a tumor tissue-based next-generation sequencing (NGS) test, for all patients except those enrolled in China, where OncoScreen Plus® was used instead [6]. This evidence concerns the gene AKT1 and neoplasm.